<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002286</url>
  </required_header>
  <id_info>
    <org_study_id>014F</org_study_id>
    <secondary_id>16</secondary_id>
    <nct_id>NCT00002286</nct_id>
  </id_info>
  <brief_title>A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients</brief_title>
  <official_title>Retrovir Capsules in the Treatment of Psoriasis in HIV Antibody Positive Patients: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the feasibility of Retrovir (AZT) in the treatment of psoriasis in HIV antibody&#xD;
      positive patients. Retrovir has been shown to be effective in the treatment of AIDS. In&#xD;
      addition, the administration of AZT appears to have induced a remission of psoriasis in one&#xD;
      case study. In light of AZT's antiviral activity and potential effectiveness as an agent for&#xD;
      the treatment of psoriasis, this would be the most likely treatment for HIV positive,&#xD;
      psoriatic patients whose disease progresses quickly.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Study participants must have biopsy-proven psoriasis with 3 distinct psoriatic lesions.&#xD;
        (Biopsy-proven Reiter's syndrome patients with 3 distinct cutaneous lesions may be&#xD;
        included.) Documented HIV antibody (by federally licensed ELISA test) positive patients.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Presence of any active opportunistic infection.&#xD;
&#xD;
          -  Presence of any AIDS-defining neoplasms (excluding Kaposi's sarcoma) such as central&#xD;
             nervous system (CNS) lymphoma.&#xD;
&#xD;
          -  Known hypersensitivity to zidovudine (AZT).&#xD;
&#xD;
          -  Impaired renal function.&#xD;
&#xD;
          -  Significant hepatic dysfunction.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        - Topical steroid, anthralin, or tar preparations. Etretinate, methotrexate, or psoralen&#xD;
        ultraviolet A (PUVA) therapy. Psoriatic treatment such as systemic agents or topical&#xD;
        steroids (emollients used distal to the control lesions and antipruritic shampoos are&#xD;
        admissible).&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Presence of any active opportunistic infection.&#xD;
&#xD;
          -  Presence of any AIDS-defining neoplasms (excluding Kaposi's sarcoma) such as central&#xD;
             nervous system (CNS) lymphoma.&#xD;
&#xD;
          -  Known hypersensitivity to zidovudine (AZT).&#xD;
&#xD;
          -  Impaired renal function.&#xD;
&#xD;
          -  Significant hepatic dysfunction.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other antiretroviral agents (e.g., suramin, ribavirin, HPA-23, dideoxycytidine).&#xD;
&#xD;
          -  Excluded within 2 weeks of study entry:&#xD;
&#xD;
          -  Topical steroid, anthralin, or tar preparations.&#xD;
&#xD;
          -  Any other experimental therapy drugs which cause significant bone marrow suppression&#xD;
             such as antifolates or pyrimethamine.&#xD;
&#xD;
          -  Cytolytic chemotherapy.&#xD;
&#xD;
          -  Drugs which cause significant nephrotoxicity or hepatotoxicity.&#xD;
&#xD;
          -  Rifampin or rifampin derivatives.&#xD;
&#xD;
          -  Excluded within 4 weeks of study entry:&#xD;
&#xD;
          -  Etretinate, methotrexate, or psoralen ultraviolet A (PUVA) therapy.&#xD;
&#xD;
          -  Excluded within 8 weeks of study entry:&#xD;
&#xD;
          -  Immunomodulating agents, including steroids, interferon, Isoprinosine, and interleukin&#xD;
             2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Glaxo Wellcome Inc</name>
      <address>
        <city>Research Triangle Park</city>
        <state>North Carolina</state>
        <zip>27709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 1989</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Pilot Projects</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

